Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

Individuals assigned male at birth who were pushed to change their identity had more inflammation and higher blood pressure.

The novel CETP inhibitor, once tested for the now-defunct pathway of HDL raising, reduces LDL as well as Lp(a).

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

The main message is that absolute levels of Lp(a) matter more than which genes may have caused them, Robert Clarke says.

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.

It’s not as “perfect as they are selling it,” but it does avoid the more catastrophic complications of thermal ablation, says ...

With both new and revised measures, the document’s authors aim to provide clinicians usable advice in a digestible format.

The tool is less apt to overestimate ASCVD risk than the pooled cohort equations and in turn could reduce overtreatment.